News
Ready-to-Dilute Pemfexy Gains Additional NSCLC Indication
The ready-to-dilute formulation was developed to eliminate the reconstitution step with Alimta.
Your search for non small cell lung cancer returned 67 results
News
Krazati Approved for KRASG12C-Mutated Locally Advanced or Metastatic NSCLC
Krazati is a highly selective and potent oral small molecule inhibitor of KRASG12C.
News
Imjudo Plus Imfinzi and Chemotherapy Approved for Metastatic NSCLC
The approval was based on data from a phase 3 POSEIDON study.
News
Libtayo Plus Chemotherapy Approved as First-Line Treatment for Advanced NSCLC
Findings showed that treatment with cemiplimab-rwlc plus platinum-based chemotherapy demonstrated a statistically significant improvement in overall survival.
News
Bevacizumab Biosimilar Alymsys Now Available
Alymsys is a vascular endothelial growth factor inhibitor.
Drugs in the Pipeline
Sapanisertib Fast Tracked for NRF2-Mutated Squamous NSCLC
Sapanisertib is a dual mTORC 1/2 inhibitor that targets a key survival mechanism in KEAP1/NRF2-mutated tumor cells.
News
Bevacizumab Biosimilar Vegzelma Gets FDA Approval
Vegzelma is a vascular endothelial growth factor inhibitor.
News
Retevmo Approved for RET-Driven Solid Tumors, NSCLC
The approvals were based on data from the LIBRETTO-001 trial.
News
Enhertu Gets Accelerated Approval for HER2-Mutant Metastatic NSCLC
The accelerated approval was based on data from the phase 2 DESTINY-Lung02 trial that included adults with HER2-mutant metastatic NSCLC after 1 prior systemic therapy.
News
Tabrecta Granted Full Approval for Metastatic NSCLC Based on Confirmatory Data
The full approval was based on data from an additional 63 adults with metastatic NSCLC with confirmed MET exon 14 skipping as well as 22 months of follow-up time.
